Abstract:Introduction: Cervical cancer (CC) is a type of cancer with poor prognosis when diagnosed in advanced stage with a big socioeconomic burden. The incidence rates have wide variations among European countries depending on the implementation or not of screening, vaccination programs and the human development index (HDI). Most studies on cost-effectiveness of CC screening programs are carried out in countries with a high HDI, however more recent reviews of screening approaches are coming from countries with lower HDI aiming to identify the best screening strategies. Our study aims to identify which are the currently applied and most cost-effective strategies of CC screening in Europe. Materials and methods: This is a systematic review conducted in three different databases (PubMed, Scopus and ScienceDirect) and reported following the PRISMA guidelines. General key terms for all databases were the following: cost-effectiveness, cervical cancer, screening, Europe. We included studies in English, Italian, Spanish and Bulgarian, published in the last 25 years, reporting data on cost-effectiveness of CC screening, costs and outcome measures. The methodological quality of the articles was evaluated with a standardized tool. Results: A total of 262 studies were identified and 22 studies were included in the final analysis. In 90.1 % of the economic studies, the new screening strategy was shown to be more cost-effective compared to the current one or compared to no screening. The optimal strategy mostly involved primary HPV testing, combined with cytology or as stand-alone screening technique. Several scenarios differing on starting age and periodicities for CC screening, combination of techniques and triage, were found to be cost-effective and below the willingness to pay (WTP) threshold. The methodology of all included studies was assessed from 10 to 11 on the JBI standardized tool and Drummond 11-point checklist. Conclusion: Numerous cost-effective options for CC screening in different European countries were identified in this systematic review. HPV testing, with or without cytology, mainly starting at 30 years of age and repeated every 5 years or more was the most cost-effective technique. Future studies should focus on the most appropriate CC screening approach for each context and setting, also considering HPV vaccination in Europe.

Policy brief Belgian EBCP mirror group 'prevention' and 'early detection & screening' in cancer

Introduction to the Supplement 'Coming together to fight cancer: a series of policy briefs taking stock of the implementation of Europe's Beating Cancer Plan in Belgium'

Policy brief Belgian EBCP Mirror Group patient and citizen engagement

Policy brief Belgian EBCP mirror group Artificial Intelligence in cancer care

Policy brief - cancer research in Belgium

Barriers and facilitators to cervical cancer screening among under- and neverscreened women in Flanders, Belgium – a qualitative study on community and healthcare providers' perspectives

Contextual factors influencing the equitable implementation of precision medicine in routine cancer care in Belgium

Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer

Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening

Policy Brief – Survivorship is cancer survivorship the poor cousin of cancer control within the EBCP?

Policy brief of the Belgian Europe's Beating Cancer Plan mirror group: children, adolescents and young adults with cancer

Expanding eligibility and improving quality of cervical cancer screening in Estonia: The 2021 reforms

HPV detection and/or cytological diagnostics

Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study

Enhancing equity in cervical screening – initiatives to increase screening participation

A synthesis of evidence for cancer-specific screening interventions: A Preventive Medicine Golden Jubilee Review

Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study

Experiences and Perceptions of Cervical Cancer Screening Using Self-Sampling among Under-Screened Women in Flanders

Evolution of European prostate cancer screening protocols and summary of ongoing trials

Systematic review of cost-effectiveness studies on cervical cancer screening across Europe

The ESSAG-trial protocol: A randomized controlled trial evaluating the efficacy of offering a self-sampling kit by the GP to reach women underscreened in the routine cervical cancer screening program